ストックスクリーナーアプリを入手
16.86
0.48%
0.08
プレマーケット:
15.47
-1.39
-8.24%
前日終値:
$16.78
開ける：
$18
24時間の取引高:
17,326
Relative Volume:
1.84
時価総額：
$5.64B
収益：
$417.75M
当期純損益:
$32.27M
株価収益率:
172.92
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.63%
1か月 パフォーマンス:
+6.57%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$16.77
$18.00
1週間の範囲:
$15.54
$18.04
52週間の値動き範囲:
$14.01
$18.04
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.86 | 5.64B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - StockTitan
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - The Australian Financial Review
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):